Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients
暂无分享,去创建一个
S. Hendrix | R. Stern | S. Coons | M. Gordon | D. Stephenson | M. Ropacki | K. Hannesdottir | Critical Path Institute’s Coalition Against Major Diseases Group
[1] Jeffrey Cummings,et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials , 2016, Journal of Neurology, Neurosurgery & Psychiatry.
[2] T. Krahnke,et al. Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies , 2016, Alzheimer's Research & Therapy.
[3] Mark Forrest Gordon,et al. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase , 2016, Alzheimer's & Dementia.
[5] E. Siemers,et al. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). , 2015, The journal of prevention of Alzheimer's disease.
[6] D. Harvey,et al. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease , 2015, Alzheimer's & Dementia.
[7] M. Colin Ard,et al. Optimal composite scores for longitudinal clinical trials under the linear mixed effects model , 2016 .
[8] Kaori Ito,et al. Development of a straightforward and sensitive scale for MCI and early AD clinical trials , 2015, Alzheimer's & Dementia.
[9] A. Fagan,et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease , 2015, Alzheimer's & Dementia.
[10] Laurie Burke,et al. Patient-Focused Drug Development: A New Direction for Collaboration , 2015, Medical care.
[11] Karen L. Price,et al. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. , 2014, Journal of Alzheimer's disease : JAD.
[12] Richard J. Caselli,et al. Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools? , 2014, Alzheimer's & Dementia.
[13] J. Cummings,et al. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.
[14] D. Shera,et al. VALIDATION OF NOVEL COMPOSITE OUTCOME MEASURES FOR PRE-DEMENTIA ALZHEIMER'S DISEASE , 2014, Alzheimer's & Dementia.
[15] N. Raghavan,et al. RETROFITTING EXISTING TOOLS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM , 2014, Alzheimer's & Dementia.
[16] P. Annas,et al. Psychometric evaluation of ADAS‐Cog and NTB for measuring drug response , 2014, Acta neurologica Scandinavica.
[17] A. Fleisher,et al. The neuropsychology of normal aging and preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.
[18] C. Jack,et al. Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases , 2013, Therapeutic innovation & regulatory science.
[19] A. Berger,et al. Psychometric features of the ADAS-Cog: Identifying a potential cognition endpoint for prodromal Alzheimer's disease , 2013, Alzheimer's & Dementia.
[20] J. Vilalta-Franch,et al. Factors Associated With the Variability in Caregiver Assessments of the Capacities of Patients With Alzheimer Disease , 2013, Journal of geriatric psychiatry and neurology.
[21] Nandini Raghavan,et al. The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials , 2013, Alzheimer's & Dementia.
[22] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[23] J. Lucas,et al. Diagnostic accuracy of the MMSE in detecting probable and possible Alzheimer's disease in ethnically diverse highly educated individuals: an analysis of the NACC database. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.
[24] Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time , 2012, Alzheimer's Research & Therapy.
[25] Clifford R Jack,et al. Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.
[26] L. Burke,et al. The Patient‐Reported Outcome (PRO) Consortium: Filling Measurement Gaps for PRO End Points to Support Labeling Claims , 2011, Clinical pharmacology and therapeutics.
[27] Bruno Vellas,et al. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials , 2011, Alzheimer's & Dementia.
[28] S. Chieffi,et al. Anosognosia for memory deficit in amnestic mild cognitive impairment and Alzheimer's disease , 2011, International journal of geriatric psychiatry.
[29] R. Petersen. Clinical practice. Mild cognitive impairment. , 2011, The New England journal of medicine.
[30] Viswanath Devanarayan,et al. Derivation of a New ADAS-cog Composite Using Tree-based Multivariate Analysis: Prediction of Conversion From Mild Cognitive Impairment to Alzheimer Disease , 2011, Alzheimer disease and associated disorders.
[31] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[32] Jessica C. Payne-Murphy,et al. Trajectory of mild cognitive impairment onset , 2008, Journal of the International Neuropsychological Society.
[33] Martin Koller,et al. A neuropsychological test battery for use in Alzheimer disease clinical trials. , 2007, Archives of neurology.
[34] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[35] R. Petersen,et al. Mild cognitive impairment , 2006, The Lancet.
[36] C. Jack,et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.
[37] Kimberly Schafer,et al. Interobserver Disagreements on Clinical Dementia Rating Assessment: Interpretation and Implications for Training , 2001, Alzheimer disease and associated disorders.
[38] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[39] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[40] T. Kurosaki,et al. Measurement of functional activities in older adults in the community. , 1982, Journal of gerontology.
[41] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.